The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
Open accessAbstract
Zoledronic acid 5 mg (ZOL) annually for 3 years reduces fracture risk in postmenopausal women with osteoporosis. To investigate long-term effects of ZOL on bone mineral density (BMD) and fracture risk, the Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly–Pivotal Fracture Trial (HORIZON-PFT) was extended to 6 years. In this international, multicenter, double-blind, placebo-controlled extension trial, 1233 postmenopausal women who received ZOL for 3 years in the core study were randomized to 3 additional years of ZOL (Z6, n = 616) or placebo (Z3P3, n = 617). The primary endpoint was femoral neck (FN) BMD percentage change from year 3 to 6 in the intent-to-treat (ITT) population. Secondary endpoints included other BMD sites, fractures, biochemical bone turnover markers, and safety. In years 3 to 6, FN-BMD remained constant in Z6 and dropped slightly in Z3P3 (between-treatment difference = 1.04%; 95% confidence interval 0.4 to 1.7; p = 0.0009) but remained above pretreatment levels. Other BMD sites showed similar differences. Biochemical markers remained constant in Z6 but rose slightly in Z3P3, remaining well below pretreatment levels in both. New morphometric vertebral fractures were lower in the Z6 (n = 14) versus Z3P3 (n = 30) group (odds ratio = 0.51; p = 0.035), whereas other fractures were not different. Significantly more Z6 patients had a transient increase in serum creatinine >0.5 mg/dL (0.65% versus 2.94% in Z3P3). Nonsignificant increases in Z6 of atrial fibrillation serious adverse events (2.0% versus 1.1% in Z3P3; p = 0.26) and stroke (3.1% versus 1.5% in Z3P3; p = 0.06) were seen. Postdose symptoms were similar in both groups. Reports of hypertension were significantly lower in Z6 versus Z3P3 (7.8% versus 15.1%, p < 0.001). Small differences in bone density and markers in those who continued versus those who stopped treatment suggest residual effects, and therefore, after 3 years of annual ZOL, many patients may discontinue therapy up to 3 years. However, vertebral fracture reductions suggest that those at high fracture risk, particularly vertebral fracture, may benefit by continued treatment. (ClinicalTrials.gov identifier: NCT00145327). © 2012 American Society for Bone and Mineral Research
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence of efficacy beyond 5 years is limited, whereas rare safety concerns such as ONJ and atypical femur fractures become more common beyond 5 years [67, 92].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [92]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Evidence of efficacy beyond 5 years is limited, whereas rare safety concerns such as ONJ and atypical femur fractures become more common beyond 5 years [67, 92].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [92]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple imputation after 18+ years
Rubin, D. B. (1996) · Journal of the American Statistical Association · doi:10.1080/01621459.1996.10476908 · Cited by 4,072
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationOnce-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citationMultiple Imputation After 18+ Years
Rubin, D. B. (1996) · Journal of the American Statistical Association · doi:10.2307/2291635 · Cited by 2,686
Cummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277
Self-citationShane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
Self-citationZoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003
Self-citationEffect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationRisk of New Vertebral Fracture in the Year Following a Fracture
Lindsay, R. (2001) · JAMA · doi:10.1001/jama.285.3.320 · Cited by 1,876
Flagged first, then by citations
Research works printed but not linked: 2
- Black, 2004, A 5-year randomized trial of the long-term efficacy and safety of alendronate: the FIT Long-term EXtension (FLEX), J Bone Miner Res., 19
- Cosman, 2011, After 3 years of IV zoledronic acid administration, who is at highest risk for subsequent vertebral fractures and who should remain on treatment?, J Bone Miner Res., 26
Cited by
Sorted by citations
Items 501–600 of 699
The use of bisphosphonates for the treatment and prevention of osteoporosis
Nikitinskaya, O. A., & Toroptsova, N. V. (2022) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2022-4-105-110 · Cited by 2
Khan, T., Sinha, P. S., & Rosen, H. N. (2023) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.90a.22071 · Cited by 2
Association between bisphosphonate use and stroke risk: a meta-analysis
Lin, S., Lin, J.-Y., Tu, Y., Wu, C., Peng, C. C., Munir, K. M., Bukhari, K., Jaggon, K. S., Fu, Y., Loh, C., et al. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06781-z · Cited by 2
Bisphosphonate drug holidays in osteoporosis according to fracture risk profile
Chamizo, A. S., Peris, P., López‐Medina, C., Flórez, H., Barceló, M. J., Pastor, M. P., Ros, I., Grados, D., Aguado, P., García, S., et al. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07309-9 · Cited by 2
Etxeberría, A., Iribar, J., Hernando, J., Idarreta, I., Vergara, I., Mozo, C., Vrotsou, K., Belzunegui, J. M., & Lekuona, A. (2016) · Gaceta Sanitaria · doi:10.1016/j.gaceta.2016.07.003 · Cited by 2
Caso clínico a debate: vacaciones terapéuticas, ¿sí o no?
Nogués, X., Casado, E., Díaz Curiel, M., Gimeno, E. J., Eslava, A. T., Henríquez, M. S., Romero, J. G. D. T., & Malouf, J. (2014) · Revista de Osteoporosis y Metabolismo Mineral · doi:10.4321/s1889-836x2014000400009 · Cited by 2
Special Committee on Medication-Related Osteonecrosis of the Jaws:
Ruggiero, S. L., Dodson, T. B., Goodday, R. H. B., Aghaloo, T. L., & Mehrotra, B. (2014) · Cited by 2
Бісфосфонати: питання тривалості терапії і докази ефективності в реальній клінічній практиці
Holovach, I. Y. (2016) · TRAUMA · doi:10.22141/1608-1706.4.17.2016.77486 · Cited by 2
Denosumab – a new medication in the treatment of postmenopausal osteoporosis
Słopień, R., Rynio, P., Kubala, E., Milewska, E., & Męczekalski, B. (2017) · Menopause Review/Przegląd Menopauzalny · doi:10.5114/pm.2017.70581 · Cited by 3
Sclerostin Modulation Holds Promise for Dental Indications
Hassan, M. G., Zaher, A. R., Palomo, J. M., & Palomo, L. (2018) · Healthcare · doi:10.3390/healthcare6040134 · Cited by 2
Second Colombian Consensus on the Management of Post-menopausal Osteoporosis: 2017 update
Orjuela, A. M., Olarte, Ó. R., Rueda-Plata, P. N., Escobar, F. S., Chalem, M., Reyes, M., González, A. R., Lozano, A. T., Talero, A. P., Rueda, C., et al. (2018) · Revista Colombiana de Reumatología (English Edition) · doi:10.1016/j.rcreue.2019.01.004 · Cited by 2
Denosumab: Mechanisms and Therapeutic Effects in the Treatment of Osteoporosis
Lewiecki, E. M. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-319-69287-6_15 · Cited by 3
Friedman, J., Farmer, A., & Fister, J. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-50695-7_25 · Cited by 2
Macías, J. G., & Olmos, J. M. (2022) · Medicina Clínica · doi:10.1016/j.medcli.2022.04.003 · Cited by 2
Abu-Jwead, A., Fisher, D. L., Goldabart, A., Yoel, U., Press, Y., Tsur, A., Fraenkel, M., & Baraf, L. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae172 · Cited by 3
Clarke, B. L. (2012) · Yearbook of Endocrinology · doi:10.1016/j.yend.2012.03.050 · Cited by 2
Postmenopausal Osteoporosis Treatment Update
Wong, E. K. C., & Παπαϊωάννου, Α. (2018) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-018-0098-y · Cited by 2
Necrosis BRONJ of the mandible, complicated by Actinomyces infection – Case Report
Gawęda, A., Kałuża, A., Wojciechowicz, J., Wachowicz, M., & Dweik, S. (2018) · Journal of Pre-Clinical and Clinical Research · doi:10.26444/jpccr/94379 · Cited by 2
Bone Diseases and Dental Implant Treatment
Guo, Y.-C., & Yuan, Q. (2019) · Springer eBooks · doi:10.1007/978-3-030-28557-9_5 · Cited by 2
Long-term treatment strategies and goal-directed therapy
Ferrari, S., & Cosman, F. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00082-4 · Cited by 2
Self-citationChallenges in Screening and Diagnosis of Osteoporosis
Cusano, N. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-83951-2_1 · Cited by 2
Miller, P. D., & Watts, N. B. (2013) · Wiley eBooks · doi:10.1002/9781118316290.ch9 · Cited by 2
Stroke following zoledronic acid infusion: effect of treatment or coincidence?
Erol, A. M., Çelik, C., Yalbuzdağ, Ş. A., & Senturk, B. (2015) · Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi · doi:10.5152/tftrd.2014.98475 · Cited by 1
Min, S., Shin, H. D., Heo, Y. M., Park, S.-E., & Lee, S. H. (2021) · Archives of Hand and Microsurgery · doi:10.12790/ahm.21.0098 · Cited by 1
Chmiel, C., Valentin, S., Beise, U., & Huber, F. (2023) · Praxis · doi:10.1024/1661-8157/a003958 · Cited by 1
Kim, H. J., Chang, H. K., Chang, D., Ha, J., Keum, B., & Kim, G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113820 · Cited by 1
Morin, S. N., Feldman, S., Funnell, L., Giangregorio, L., Kim, S. S. Y., McDonald-Blumer, H., Santesso, N. A., Ridout, R., Ward, W. E., Ashe, M. C., et al. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.221647-f · Cited by 1
Lehmann, O., Mineeva, O., Veshchezerova, D., Häuselmann, H., Guyer, L., Reichenbach, S., Lehmann, T., Demler, O., Everts‐Graber, J., The Swiss Osteoporosis Registry Study Group, et al. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae089 · Cited by 2
Iba, K., Hanaka, M., Emori, M., Takashima, K., Teramoto, A., & Takada, J. (2024) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2024.j124 · Cited by 1
Identification and Management of Late Toxicities After Radiation Therapy for Vulvar Cancer
DeCesaris, C. M., Bedell, S., Gaffney, D. K., Suneja, G., Burt, L., & Brower, J. V. (2025) · Practical Radiation Oncology · doi:10.1016/j.prro.2025.05.010 · Cited by 1
Research Status and Hot Spot Visualization Analysis of Osteoporosis from 2014 to 2025
Huang, Y., Wang, F., Lian, K., Li, L., & Wang, Z. (2025) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s541592 · Cited by 2
Tweekittikul, A., Srinonprasert, V., & Sura-amonrattana, U. (2025) · BMC Geriatrics · doi:10.1186/s12877-025-06689-9 · Cited by 1
Clarifying clinically treatment-naive status for osteoporosis patients
Kendler, D. L., Habert, J., Khan, A. A., Kherani, R. B., Kim, S. S. Y., Kovács, C. S., Lee, J., Purvis, J., Reis, J., Slatkovska, L., et al. (2026) · Osteoporosis International · doi:10.1007/s00198-026-07864-3 · Cited by 1
Nakafero, G., McKeever, T., Kumar, N. S., Welsh, V. K., Müller, S., & Abhishek, A. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002085 · Cited by 1
Jha, V., Bhadada, S. K., Mukherjee, S., Pal, R., & Kharbanda, C. (2026) · Bone · doi:10.1016/j.bone.2026.118003 · Cited by 1
Christensen, D. H., Horváth–Puhó, E., Schmidt, M., Christiansen, C. F., Pedersen, L. H., Langdahl, B. L., & Thomsen, R. W. (2015) · Clinical Epidemiology · doi:10.2147/clep.s85427 · Cited by 1
Gosselin, J., Bougnères, C., Bennet, P., Avenel, G., Vittecoq, O., & Daragon, A. (2015) · Revue du Rhumatisme · doi:10.1016/j.rhum.2015.01.001 · Cited by 1
Abadzhiev, M. (2015) · InTech eBooks · doi:10.5772/61731 · Cited by 1
Effect of Stopping Risedronate after Long-Term Treatment on Bone Turnover
Clarke, B. L. (2012) · Yearbook of Medicine · doi:10.1016/s0084-3873(12)00327-6 · Cited by 1
Skeletal Fragility, a Common Menopausal Burden: Risk Assessment, Diagnosis, and Management
Holick, M. F. (2017) · Springer eBooks · doi:10.1007/978-3-319-42451-4_8 · Cited by 1
Femur shaft complete fractures associated with misdiagnosed stress fractures due to bisphosphonates
Çiftçi, S., Terlemez, R., Duman, Z., Doğu, B., Öncü, J., Yılmaz, F., & Kuran, B. (2017) · European Geriatric Medicine · doi:10.1016/j.eurger.2017.02.005 · Cited by 1
Ota, S., & Yasuda, T. (2017) · Modern Rheumatology Case Reports · doi:10.1080/24725625.2017.1303863 · Cited by 1
Denosumab for the Treatment of Osteoporosis
McClung, M. R. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00083-2 · Cited by 1
Osteoporotic Vertebral Fractures
Telera, S. M., Raus, L., Pipola, V., Iure, F. D., & Gasbarrini, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-76555-2_9 · Cited by 1
Impact of a Bisphosphonate Drug Holiday on the Bone Mineral Density in Patients with Osteoporosis
Rutendo, R., Mohamed, F., & Raal, F. J. (2021) · Wits Journal of Clinical Medicine · doi:10.18772/26180197.2021.v3n2a2 · Cited by 1
Effect of Stopping Risedronate after Long-Term Treatment on Bone Turnover
Clarke, B. L. (2012) · Yearbook of Endocrinology · doi:10.1016/j.yend.2012.03.049 · Cited by 1
Marchenkova, L. (2022) · Bulletin of Rehabilitation Medicine · doi:10.38025/2078-1962-2022-21-2-139-149 · Cited by 1
Wang, H., Liu, Q., Jiang, M.-H., Song, C.-L., & Liu, D.-Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1089774 · Cited by 1
Long-term treatment with bisphosphonates in clinical practice: advantages, main problems and risks
Shkireeva, S. Y., & Lesnyak, O. M. (2024) · Osteoporosis and Bone Diseases · doi:10.14341/osteo13157 · Cited by 1
Riska, B. S. L., Gunnes, N., Finnes, T. E., Meyer, H. E., Hoff, M., Omsland, T. K., & Holvik, K. (2024) · Archives of Osteoporosis · doi:10.1007/s11657-024-01458-4 · Cited by 1
Osteoporosis in Older Men: Informing Patient Management and Improving Health-Related Outcomes
Ruggiero, C., Caffarelli, C., Calsolaro, V., Tafaro, L., Riuzzi, F., Bubba, V., Napoli, N., Ferracci, M., Mecocci, P., Giusti, A., et al. (2025) · Drugs & Aging · doi:10.1007/s40266-024-01163-4 · Cited by 1
Tan, M. Z., Chionh, S. B., & Chandran, M. (2012) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.027.02.05 · Cited by 1
Self-citationBisphosphonates: forever or 5 years and stop?
Kolber, M. R., Sadowski, C. A., & Korownyk, C. S. (2015) · Europe PMC (PubMed Central) · Cited by 1
Bisphosphonates Zoledronate and Alendronate for the Management of Postmenopausal Osteoporosis
Radwan, I. A., Korany, N. S., & Ezzat, B. A. (2018) · Case Reports in Clinical Medicine · doi:10.4236/crcm.2018.75030 · Cited by 1
Personalisierte Osteoporose-Therapie
Schulz, K., Kalscheuer, H., & Lehnert, H. (2019) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0841-8336 · Cited by 1
Clinical Management of Patients Older than 75 Years of Age With Fractures of the Proximal Femur
Zagorodny, N. V., Volna, A., & Panfilov, I. I. (2016) · Russian Osteopathic Journal · doi:10.32885/2220-0975-2016-3-4-30-38 · Cited by 1
Landis, M. N., & Adams, D. R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-61211-1.00039-5 · Cited by 1
Risk of spontaneous vertebral fracture during bisphosphonates drug holiday
Aboughanima, A. (2020) · Egyptian Rheumatology and Rehabilitation · doi:10.1186/s43166-020-00027-0 · Cited by 1
Improving Bisphosphonate Use and Evaluation in a Rural Family Medicine Practice
Adelman, M., Assadzandi, S., & Xiang, J. (2021) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2021.152 · Cited by 1
Adler, R. A. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-319-69287-6_20 · Cited by 1
Menopausal osteoporosis in the practice of a gynecologist
Kuznetsova, I. V., & Chilova, R. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-12-320-331 · Cited by 1
Screening Strategies for Treatment of Osteoporosis in Long‐Term Care Residents
Shil, A. B., & Greer, J. R. (2012) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12024 · Cited by 1
Acute Medical Aspects Related to Osteoporosis and Its Therapy
Diab, D. L., & Watts, N. B. (2018) · Wiley eBooks · doi:10.1002/9781119374800.ch26 · Cited by 1
Fu, S., & Sheng, Z. (2017) · Osteoporosis International · doi:10.1007/s00198-016-3867-1 · Cited by 1
Drug holidays in osteoporosis treatment: mind the gaps!
Anagnostis, P. G., Lambrinoudaki, I. V., Kenanidis, E. I., Potoupnis, M. E., Tsiridis, E. E., & Goulis, D. G. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05027-1 · Cited by 1
Graef, J. L. (2016) · SHAREOK (University of Oklahoma; Oklahoma State University; Central Oklahoma University) · Cited by 1
ERKRANKUNGEN DER ENDOKRINEN ORGANE UND DES STOFFWECHSELS
Jung, N., Mayet, W.-J., Mertens, P. R., Meyer, J. S., Müller, O.-A., Pfeifer, M., Schellinger, P. D., Weiss, N., & Wendtner, C.-M. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-06282-7.50015-2 · Cited by 1
Bisphosphonate holidays: using cost-effectiveness analysis for the “yes, but” questions
Colon-Emeric, C. S., & Lee, R. H. (2021) · Osteoporosis International · doi:10.1007/s00198-021-06064-5 · Cited by 1
Tanaka, M., Mori, H., & Kawabata, K. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-0017-2
Epidemiology of Fracture in Adults with Kidney Disease
Naylor, K. L. (2015) · Scholarship@Western (Western University)
Atypical osteoporotic fractures: impact on therapeutic decision making in osteoporosis.
Ish‐Shalom, S. (2014) · PubMed
Stanford, P. E. (2012) · Clinical Medicine Reviews in Therapeutics · doi:10.4137/cmrt.s3393
Bisfosfonatos intravenosos en la enfermedad ósea de Paget: mayor riesgo de efectos secundarios
Grados, D., Martínez‐Morillo, M., Holgado, S., & Erra, A. (2013) · Medicina Clínica · doi:10.1016/j.medcli.2013.07.017
Andrews, N. A. (2012) · IBMS BoneKEy · doi:10.1038/bonekey.2012.151
Rotation des traitements anti-ostéoporotiques
Briot, K. (2011) · Revue du Rhumatisme · doi:10.1016/s1169-8330(11)70041-2
Plotkin, L. I. (2014) · Revista de Osteoporosis y Metabolismo Mineral · doi:10.4321/s1889-836x2014000200001
Treatment holidays in patients with postmenopausal osteoporosis: Whom and when?
Reyes‐García, R., Martín, A. G., & Muñoz‐Torres, M. (2012) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2012.07.010
Smith, A., Shaw, B., Laliberte, D., Langston, J., & Bushardt, R. L. (2013) · JAAPA · doi:10.1097/01.jaa.0000432496.47021.62
Duration of Bisphosphonate Treatment
Kim, K. M., & Rhee, Y. (2014) · Korean Journal of Medicine · doi:10.3904/kjm.2014.87.2.151
Current Status of Potent Bone Resorption Antagonists
Leung, P. (2014) · Journal of Osteoporosis and Physical Activity · doi:10.4172/2329-9509.1000129
Self-citationRecent advances in the risk assessment and treatment of osteoporosis
Compston, J. E. (2012) · Clinical Medicine · doi:10.7861/clinmedicine.12-6-s2
Long-term extension trials to prove the efficacy and safety of bisphosphonates
Miller, P. D. (2013) · Clinical Investigation · doi:10.4155/cli.13.113
Minisola, S., & Romagnoli, E. (2013) · Medical radiology · doi:10.1007/174_2012_651
Vacaciones terapéuticas en pacientes con osteoporosis posmenopáusica: ¿a quién y cuándo?
Reyes‐García, R., Martín, A. G., & Muñoz‐Torres, M. (2012) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.07.009
For how long should osteoporosis treatment continue?
Boschitsch, E. (2015) · Climacteric · doi:10.3109/13697137.2015.1065061
Frakturprävention bei der älteren Frau
Lippuner, K. (2015) · Gynäkologische Endokrinologie · doi:10.1007/s10304-014-0647-x
Self-citationBrown, J. P., Morin, S. N., Leslie, W. D., Παπαϊωάννου, Α., Cheung, A. M., Davison, K. S., Goltzman, D., Hanley, D. A., Hodsman, A. B., Josse, R., et al. (2014) · Europe PMC (PubMed Central)
Long-Term Management and Monitoring of Osteoporosis
Watts, N. B. (2015) · The Endocrine Society eBooks · doi:10.1210/mtp4.9781936704941.ch10
Huang, S., Lin, H. V., Zhu, X.-F., Chen, X., Fan, L., & Liu, C. (2014)
What is needed to advance the treatment of osteoporosis in the UK?
Dulay, G., & Dennison, E. M. (2015) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.15.31
Ostéoporose pendant la ménopause
Khan, A. A., & Fortier, M. P. (2016) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2016.09.057
How Long to Treat with Bisphosphonates?
Alshahrani, F., & Almalki, M. (2015) · Health · doi:10.4236/health.2015.712174
Osteoporosis and the Orthopedist
Leung, P. (2014) · Orthopedic & Muscular System · doi:10.4172/2161-0533.s2-006
Self-citationTratamiento de la osteoporosis: riesgos y beneficios de los bifosfonatos a largo plazo
Botargues, M., Arceo, M. D., Ricci, R. I., Ganiele, M. D. L. N., & Vietto, V. (2013)
Tratamiento de la osteoporosis en pacientes de alto riesgo: El manejo del internista
Álvarez, A. A., Cano, M. R., Orozco, M. R., Greene, E. J. D., & Weber, F. L. R. (2013) · Acta Médica Grupo Ángeles
Paccou, J. (2016) · Revue du Rhumatisme · doi:10.1016/j.rhum.2015.11.008
Gonçalves, A. S. D. S., Rodrigues, A. M., Canhão, H. M., & Fonseca, J. E. (2013)
Bleibler, F., & König, H. (2016) · RePEc: Research Papers in Economics
Ce que les patientes doivent savoir sur le risque osseux et sa prévention
Trémollières, F. (2012) · Journal de gynécologie, obstétrique et biologie de la reproduction. Supplément/Journal de gynécologie obstétrique et biologie de la reproduction · doi:10.1016/j.jgyn.2012.09.004
Metadata
- Authors
- Black, D. M., Reid, I. R., Boonen, S., Bucci-Rechtweg, C., Cauley, J. A., Cosman, F., Cummings, S. R., Hue, T. F., Lippuner, K., Lakatos, P., Leung, P. C., Man, Z., Martinez, R. L. M., Tan, M., Ruzycky, M. E., Su, G., & Eastell, R.
- Affiliations
- University of California, San Francisco (US)
- University of Auckland (NZ)
- KU Leuven (BE)
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- University of Pittsburgh (US)
- Helen Hayes Hospital (US)
- California Pacific Medical Center (US)
- University Hospital of Bern (CH)
- Semmelweis University (HU)
- Chinese University of Hong Kong (HK)
- Centro Médico TIEMPO, Buenos Aires, Argentina
- University of Sheffield (GB)
- Corresponding author
- Black, Dennis M
- ORCID
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-12-08
- Volume
- 27
- Issue
- 2
- Pages
- 243-254
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- PMC
- PMC3427916
- OpenAlex
- W2106406207
- Cited by
- 700
- References
- 40
- Citations by year
- 2026: 18 · 2025: 37 · 2024: 29 · 2023: 45 · 2022: 40 · 2021: 58 · 2020: 53 · 2019: 49 · 2018: 48 · 2017: 54 · 2016: 61 · 2015: 62 · 2014: 50 · 2013: 49 · 2012: 35
- FWCI
- 49.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR000005)
- University of California, San Francisco
- Novartis Pharma
- National Center for Research Resources (UL1RR024153)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- zoledronic acid, osteoporosis, postmenopausal women, long-term treatment, bone mineral density, femoral neck, vertebral fractures, fracture risk, bone turnover markers, serum creatinine, atrial fibrillation, stroke, hypertension, bisphosphonates, adverse events
- MeSH terms
- Zoledronic Acid, Aged, Diphosphonates, Female, Follow-Up Studies, Humans, Imidazoles, Osteoporosis, Peptide Fragments, Procollagen, Time Factors, Biomarkers, Bone Density, Incidence, Bone Remodeling, Treatment Outcome, Bone Density Conservation Agents, Osteoporotic Fractures
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
